Pralsetinib - Latest Advances

Corneal edema and epithelial defect during pralsetinib treatment.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 29, 2025

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: June 03, 2025

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Journal: Biomarker research

Published: May 24, 2025

Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies.

Journal: Bioorganic chemistry

Published: May 06, 2025

Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.

Journal: RSC medicinal chemistry

Published: April 18, 2025

Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance.

Journal: International journal of surgery (London, England)

Published: March 29, 2025

Systemic Therapies for Advanced Medullary Thyroid Carcinoma.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

Published: March 19, 2025

Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy.

Journal: RSC medicinal chemistry

Published: March 18, 2025

Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer.

Journal: Journal of biomolecular structure & dynamics

Published: March 10, 2025

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report.

Journal: Oncotarget

Published: February 05, 2025

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib.

Journal: Frontiers in genetics

Published: February 02, 2025

Filters

Corneal edema and epithelial defect during pralsetinib treatment.

Corneal edema and epithelial defect during pralsetinib treatment.

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies.

Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies.

Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.

Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.

Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance.

Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance.

Systemic Therapies for Advanced Medullary Thyroid Carcinoma.

Systemic Therapies for Advanced Medullary Thyroid Carcinoma.

Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy.

Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy.

Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer.

Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer.

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report.

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report.

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib.

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib.